Mineralys Therapeutics, Inc. (MLYS)

NASDAQ: MLYS · IEX Real-Time Price · USD

13.20

-0.42 (-3.08%)

At close: Jul 19, 2024, 4:30 PM

13.28

+0.08 (0.61%)

Pre-market: Jul 20, 2024, 9:29 AM EDT

Mineralys Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	16.26	14.3	5.23	2.42	0.53
Research & Development	88.82	70.36	26.25	16.31	2.41
Operating Expenses	105.08	84.66	31.48	18.73	2.94
Operating Income	-105.08	-84.66	-31.48	-18.73	-2.94
Interest Expense / Income	0	0	0	-0.03	0.12
Other Expense / Income	-14.28	-12.76	-1.68	0.71	0.37
Pretax Income	-90.8	-71.9	-29.8	-19.41	-3.43
Net Income	-90.8	-71.9	-29.8	-19.41	-3.43
Shares Outstanding (Basic)	45	36	5	5	50
Shares Outstanding (Diluted)	45	36	5	5	50
Shares Change	81.31%	600.33%	3.67%	-90.03%	-
EPS (Basic)	-2.21	-1.99	-5.77	-3.89	-0.07
EPS (Diluted)	-2.21	-1.99	-5.77	-3.89	-0.07
Free Cash Flow	-87.6	-81.17	-29.22	-14.56	-2.46
Free Cash Flow Per Share	-1.95	-2.24	-5.66	-2.92	-0.05
EBITDA	-90.79	-71.9	-29.8	-19.44	-3.31
Depreciation & Amortization	0.01	0	0	0	0
EBIT	-90.8	-71.9	-29.8	-19.44	-3.31

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).